{"id":38845,"date":"2026-06-23T11:10:00","date_gmt":"2026-06-23T15:10:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38845"},"modified":"2026-05-11T08:38:05","modified_gmt":"2026-05-11T12:38:05","slug":"from-humira-to-keytruda-the-blueprint-for-surviving-the-composition-of-matter-cliff","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/from-humira-to-keytruda-the-blueprint-for-surviving-the-composition-of-matter-cliff\/","title":{"rendered":"From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

A composition of matter patent is the only piece of pharmaceutical intellectual property that a generic or biosimilar manufacturer cannot work around. Every other patent in a drug’s estate \u2014 formulation, method of use, manufacturing process, device, polymorph, salt \u2014 can theoretically be designed around or invalidated. The molecule itself cannot. When the COM patent goes, the regulatory and commercial moat that the molecule built collapses in a manner that is, by now, fairly predictable.<\/p>\n\n\n\n

What is less predictable is what the originator does about it. The answers vary by an order of magnitude. Pfizer lost roughly 80% of Lipitor’s U.S. revenue within 24 months [1]. AbbVie held Humira together for seven additional years past its core 2016 expiry through a 247-application patent thicket [2]. Merck is now attempting, with the Keytruda Qlex subcutaneous launch, to compress the most expensive lifecycle defense ever attempted into roughly three years before its 2028 cliff [3].<\/p>\n\n\n\n

The differences between these outcomes are not random. They follow a small number of structural variables \u2014 molecule type (small molecule versus biologic), regulatory pathway (Hatch-Waxman versus BPCIA), formulation complexity, payer dynamics, and the timing of secondary patent filings. Anyone modeling a pharma company’s terminal value has to model these variables together. This piece walks through how.<\/p>\n\n\n\n

What Composition of Matter Actually Protects<\/strong><\/h2>\n\n\n\n

The COM patent claims the active pharmaceutical ingredient itself: the chemical structure, salt forms, enantiomers, and for biologics, the amino acid sequence and glycosylation pattern. As DrugPatentWatch puts it in its analysis of patent layering, this is ‘the strongest patent, the one generics most want to challenge, and the one that expires first in the absence of a Patent Term Extension’ [4]. The COM filing typically precedes human trials by years, which is why the nominal 20-year USPTO term translates into a much shorter effective market exclusivity of seven to twelve years for most drugs [5].<\/p>\n\n\n\n

Three structural facts about COM expiration drive everything else:<\/p>\n\n\n\n

First, a generic or biosimilar manufacturer can replicate the molecule without infringing once the COM patent expires. The chemistry is in the patent file, by design.<\/p>\n\n\n\n

Second, regulatory exclusivities \u2014 New Chemical Entity exclusivity, Orphan Drug Exclusivity, the BPCIA’s 12-year reference product exclusivity for biologics \u2014 are independent of patents and can extend the effective monopoly past the COM expiration date. Pediatric exclusivity adds a flat six months to whatever the longest-running patent or exclusivity provides [5].<\/p>\n\n\n\n

Third, secondary patents \u2014 formulation, method-of-use, polymorph, device \u2014 do not protect the molecule. They protect specific embodiments of it. A generic manufacturer can produce the API and either design around the secondary patents, challenge them through inter partes review, or wait them out.<\/p>\n\n\n\n

The Hatch-Waxman Asymmetry for Small Molecules<\/strong><\/h3>\n\n\n\n

Under Hatch-Waxman, a generic filer submits an Abbreviated New Drug Application certifying that the drug’s listed patents are invalid, unenforceable, or not infringed (Paragraph IV certification). The first successful Paragraph IV filer gets 180 days of generic exclusivity, which is the economic incentive that drives the entire generic industry’s litigation budget. Multiple generics typically enter near-simultaneously after that window, and prices fall 80% to 90% within 12 to 18 months [6].<\/p>\n\n\n\n

This is the Lipitor model. Pfizer’s atorvastatin lost U.S. exclusivity in November 2011 after generating peak revenue near $13 billion. Within 12 months of generic entry, branded Lipitor retained a small fraction of its former share, and within two years U.S. revenue had fallen approximately 80% [7]. Worldwide revenue dropped from $9.5 billion in 2011 to $3.9 billion in 2012 \u2014 a 59% single-year collapse [8].<\/p>\n\n\n\n

The Plavix Acceleration: Faster Than Lipitor<\/strong><\/h3>\n\n\n\n

Bristol-Myers Squibb and Sanofi’s Plavix (clopidogrel) lost U.S. exclusivity in May 2012. Nine generic manufacturers received FDA approval simultaneously, which accelerated the erosion curve beyond what Lipitor had experienced six months earlier. BMS reported a 60% revenue collapse in a single quarter [42]. Analyst forecasts at the time projected BMS would lose roughly 40% of total company revenue from the combined Plavix and Avapro expirations [42].<\/p>\n\n\n\n

The Plavix erosion shape is the most instructive in the small-molecule canon because it shows what happens when multiple generic entrants hit the same exclusivity window. The 180-day generic exclusivity awarded to the first Paragraph IV filer normally produces a brief duopoly between the originator and one generic; subsequent generics enter after that window. In Plavix’s case, the timing of the litigation produced a near-simultaneous nine-generic launch, which compressed the entire price discovery process into weeks.<\/p>\n\n\n\n

The relevant lesson is that the number of generic entrants determines the depth of the cliff, while the structural attributes of the drug determine the slope of the curve down to that depth. Lipitor had high payer motivation for substitution but only a few initial generic entrants; the erosion stretched over 12\u201318 months. Plavix had nine simultaneous entrants; the erosion happened in 8\u201312 weeks.<\/p>\n\n\n\n

The Singulair Case: A Cliff That Took 90 Days<\/strong><\/h3>\n\n\n\n

Merck’s Singulair (montelukast) for asthma lost U.S. exclusivity in August 2012. The drug had generated peak revenue of $5.5 billion. Within 90 days of generic entry, Singulair’s U.S. sales had fallen approximately 80%. Within a year, the franchise was effectively a commodity.<\/p>\n\n\n\n

The Singulair experience matters because Merck had relatively strong secondary patents and an active pediatric exclusivity program. None of it slowed the cliff materially. The conclusion that Merck’s strategic planners drew from Singulair was that small-molecule lifecycle defense produces only marginal returns, and that R&D investment should be redirected toward biologics where structural advantages produce durable returns. The 2010s pivot in Merck’s portfolio mix \u2014 toward Keytruda and other complex biologics \u2014 was partly a response to Singulair.<\/p>\n\n\n\n

Nexium and the Authorized Generic Strategy<\/strong><\/h3>\n\n\n\n

AstraZeneca’s Nexium (esomeprazole) faced generic competition in 2014 but achieved a softer landing than Lipitor or Plavix through an authorized generic arrangement and a continued promotion strategy. The drug retained meaningful share for 18 months past the cliff, with revenue falling roughly 50% in the first year rather than 80%. Generic esomeprazole prices fell approximately 80% within the first two years [43].<\/p>\n\n\n\n

The Nexium playbook included an over-the-counter Nexium 24HR launch in 2014, just before generic entry, which captured roughly $400 million in annual OTC revenue and partially offset prescription losses. The OTC pathway is available to a narrow subset of drugs \u2014 those with established safety profiles and indications appropriate for self-care \u2014 but where it is available, it can recapture 10\u201320% of pre-cliff revenue.<\/p>\n\n\n\n

The BPCIA Asymmetry for Biologics<\/strong><\/h3>\n\n\n\n

The Biologics Price Competition and Innovation Act, which Congress passed in 2010, creates a parallel but structurally different pathway for biosimilars. A biosimilar applicant files a 351(k) application referencing the originator’s biological license application. The reference product gets 12 years of regulatory exclusivity. The ‘patent dance’ that follows is more permissive than Hatch-Waxman in one critical respect: the BPCIA places no statutory cap on how many patents the originator can assert against a biosimilar challenger [9].<\/p>\n\n\n\n

That gap is the loophole AbbVie drove a truck through with Humira. It is also why the patent thicket strategy works for biologics in a way it would not for small molecules under Hatch-Waxman.<\/p>\n\n\n\n

The Humira Case: Anatomy of the Most Successful Lifecycle Defense in Industry History<\/strong><\/h2>\n\n\n\n

Humira (adalimumab) received FDA approval in December 2002 for rheumatoid arthritis. By 2021, it generated $20.7 billion in revenue [10]. AbbVie earned roughly $200 billion from the product over its lifetime, the largest single-drug commercial run on record [11].<\/p>\n\n\n\n

The core COM patent on adalimumab expired in December 2016. The first U.S. biosimilar \u2014 Amgen’s Amjevita \u2014 did not launch until January 2023. That six-year gap is the lifecycle management equivalent of a moon landing.<\/p>\n\n\n\n

The 247-Application Thicket<\/strong><\/h3>\n\n\n\n

AbbVie filed 247 patent applications related to Humira and obtained at least 132 granted patents [12]. The applications covered manufacturing processes, formulation variants, dosing protocols, citrate-free formulations, high-concentration formulations, autoinjector devices, and methods of treating various indications. Almost half of those filings came after 2014 \u2014 within two years of the COM patent expiring [13].<\/p>\n\n\n\n

The economic logic was straightforward. Under the BPCIA, AbbVie could assert any or all of these patents against an incoming biosimilar. In the Boehringer Ingelheim litigation that briefly threatened to crack the thicket open, AbbVie asserted more than 60 patents against a single challenger [9]. Patent litigation of that scope is not financially survivable for most biosimilar manufacturers, even if they think most of the patents are weak.<\/p>\n\n\n\n

Settlements Built the Wall<\/strong><\/h3>\n\n\n\n

Between 2017 and 2019, AbbVie settled with at least nine biosimilar manufacturers including Amgen, Samsung Bioepis, Sandoz, Mylan, Pfizer, Boehringer Ingelheim, and others. The settlement terms followed a consistent template: biosimilars could enter the European market in October 2018, but had to stay out of the U.S. until 2023 [14]. AbbVie received ‘royalty-bearing’ licenses from each. No money changed hands in the conventional pay-for-delay sense, which is part of why the antitrust challenge failed in 2020.<\/p>\n\n\n\n

Judge Manish Shah of the Northern District of Illinois dismissed the consolidated class action in In re Humira (Adalimumab) Antitrust Litigation in June 2020, relying in part on the Noerr-Pennington doctrine, which protects petitioning conduct from antitrust liability [15]. The Seventh Circuit affirmed in 2022. The plaintiffs lost, AbbVie kept its monopoly through 2022, and the case became the canonical example of why patent thickets work under the current legal framework.<\/p>\n\n\n\n

The 2023 Erosion Was Slower Than the Lipitor Model Predicted<\/strong><\/h3>\n\n\n\n

Once biosimilars entered in 2023, Humira’s U.S. revenue fell roughly one-third in the first year, to $12.2 billion \u2014 substantial but nowhere near a Lipitor-style 80% collapse [16]. Global revenue dropped from $21.2 billion in 2022 to $14.4 billion in 2023, a 32% decline [17]. Biosimilars priced as much as 85% below Humira’s wholesale acquisition cost \u2014 Coherus’s Yusimry and Samsung Bioepis’s Hadlima led on that front \u2014 captured share more slowly than analysts expected [16].<\/p>\n\n\n\n

The 2024 picture is where the inflection point became visible. After CVS Caremark removed Humira from several major commercial formularies in April 2024 in favor of Sandoz’s Hyrimoz (operating under CVS’s Cordavis label), Humira’s market share dropped to roughly 82%, with biosimilars taking 18% [18]. Global Humira revenue for full-year 2024 was approximately $9 billion, down from $14.4 billion in 2023 \u2014 the second year erosion that finally resembled what biosimilar developers had originally projected [19].<\/p>\n\n\n\n

The Skyrizi-Rinvoq Pivot<\/strong><\/h3>\n\n\n\n

AbbVie’s structural defense was not the patent thicket \u2014 that was the time-buying tactic. The actual replacement strategy was the development and launch of Skyrizi (risankizumab-rzaa) and Rinvoq (upadacitinib), both positioned for the same indications Humira treats but with newer mechanisms and longer effective patent runways. In 2023, Skyrizi’s U.S. sales climbed to $6.8 billion, up more than $2 billion year-over-year. Rinvoq brought in $2.8 billion in U.S. sales, up from $1.8 billion [20]. By 2024, Skyrizi alone was generating quarterly revenue near $2 billion, approaching Humira’s diminished take [21].<\/p>\n\n\n\n

The handoff was deliberate, deliberate enough that AbbVie’s then-CEO Rick Gonzalez told investors 2023 would be the company’s revenue ‘floor’ before resuming growth in 2025. That floor held in part because the seven-year window the patent thicket bought was used to scale two adjacent immunology franchises into multi-billion-dollar products before the original cliff arrived.<\/p>\n\n\n\n

The Keytruda Cliff: A Real-Time Lifecycle Stress Test<\/strong><\/h2>\n\n\n\n

Merck’s pembrolizumab is the world’s best-selling drug. It generated $29.5 billion in 2024 revenue, accounting for roughly 45% of Merck’s total business [22]. The core COM patent expires in 2028, with patent term adjustments extending some claims into 2029.<\/p>\n\n\n\n

Merck has been preparing for this for years, but the visible execution accelerated in 2024\u20132025. The strategy has three legs.<\/p>\n\n\n\n

Subcutaneous Keytruda Qlex: The Product Hop<\/strong><\/h3>\n\n\n\n

On September 19, 2025, the FDA approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), a subcutaneous formulation administered as a 2-minute injection every six weeks, compared to the IV formulation’s 30-minute infusion every three weeks [23]. The reformulation uses Halozyme’s ENHANZE platform, which deploys recombinant human hyaluronidase PH20 to enable rapid subcutaneous delivery of large-volume biologics [24].<\/p>\n\n\n\n

Merck CEO Rob Davis has stated publicly that the company expects Keytruda Qlex to capture 30% to 40% of Keytruda’s U.S. patient base by 2027, transforming what he calls ‘a cliff into more of a hill’ [25]. The reformulation program reportedly cost between $500 million and $1 billion [24].<\/p>\n\n\n\n

Two patents have been issued from 17 patent applications covering the subcutaneous formulation, with claims that could extend exclusivity for the SC product into 2042 \u2014 fourteen years past the IV COM expiration [24]. Whether those claims will hold against litigation is a separate question; Merck has acknowledged that the SC patent estate does not block biosimilar IV pembrolizumab specifically. As a Merck spokesperson told Bloomberg Law, the company ‘does not expect any patent protection specifically directed to SC pembrolizumab to impact the potential marketing of a biosimilar intravenous form of Keytruda’ [26].<\/p>\n\n\n\n

That careful phrasing matters. The defense strategy is not to block IV biosimilars in court. It is to move patients off the IV formulation before biosimilars can capture them.<\/p>\n\n\n\n

The Patent Thicket Around Pembrolizumab<\/strong><\/h3>\n\n\n\n

The Initiative for Medicines, Access and Knowledge (I-MAK), an advocacy group critical of pharmaceutical patent practices, analyzed Merck’s Keytruda patent estate in 2025 and found that the company had filed over 100 additional patent applications and secured nearly 30 more patents since I-MAK’s 2022 review. Total filings reached nearly 300 patents, with over 100 granted [27]. The numerical scale matches the Humira playbook.<\/p>\n\n\n\n

In February 2023, four members of Congress wrote to the U.S. Patent and Trademark Office urging scrutiny of Merck’s Keytruda patent portfolio, citing concerns about ‘anti-competitive business practices’ including patent thicketing and product hopping [26]. The Senate Judiciary Committee approved bipartisan bills targeting product-hopping in 2025, though none have become law. Industry observers expect patent litigation over Keytruda biosimilars to begin as early as 2026, since BPCIA-driven patent disputes typically start roughly two years before the brand’s exclusivity ends [26].<\/p>\n\n\n\n

Pricing the Subcutaneous Version at Parity<\/strong><\/h3>\n\n\n\n

Merck has stated it will price Keytruda Qlex at parity to the IV formulation [28]. A three-week IV course costs near $11,800; the SC course covers six weeks. This pricing creates a per-dose discount through a longer dosing interval rather than a sticker-price cut, which preserves margin while improving the value calculation for payers.<\/p>\n\n\n\n

Davis has separately said that Merck will price aggressively against biosimilar competition: ‘We will price our subcutaneous to drive for volume… which means we will be looking at prices really more in line with where you would see a generic version at a premium that history has shown is very manageable’ [29]. The implication: parity pricing now, premium-to-generic pricing after 2028.<\/p>\n\n\n\n

What Happens If the Hop Fails<\/strong><\/h3>\n\n\n\n

Analyst forecasts that assume the Qlex strategy underperforms project Keytruda revenue collapsing roughly 80% post-2028, from $30 billion to approximately $6 billion annually [24]. The delta is roughly $24 billion in annual revenue \u2014 comparable to the entire revenue base of a top-25 pharma company.<\/p>\n\n\n\n

If the SC formulation captures Davis’s projected 30\u201340% of patients before biosimilars hit, the math improves substantially. If it captures 60%, Merck might engineer something approaching a ‘patent slope’ rather than a cliff. The Halozyme-licensed ENHANZE platform now has 10 commercialized products across 100+ global markets, with licensees including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, and others [24]. The IV-to-SC reformulation strategy is becoming a structural component of biologics lifecycle management rather than a Merck-specific experiment.<\/p>\n\n\n\n

\n

‘Between 2025 and 2030, the industry anticipates that nearly 200 drugs, including approximately 70 blockbuster medications with annual sales exceeding $1 billion each, will lose their market exclusivity. The total revenue at risk during this window is estimated to exceed $300 billion, with some projections reaching as high as $400 billion by 2033 as foundational patents for top-selling therapies like Keytruda, Eliquis, and Opdivo lapse.’ \u2014 DrugPatentWatch analysis of LOE forecasts [30]<\/p>\n<\/blockquote>\n\n\n\n

Five Defensive Layers Every Blockbuster Should Have Before Year Five<\/strong><\/h2>\n\n\n\n

The Humira and Keytruda experiences map onto a generalizable framework. A company with a blockbuster molecule has roughly five defensive layers it can deploy. The companies that survive the cliff intact deploy most of them. The companies that get Lipitored deploy two or three.<\/p>\n\n\n\n

Layer One: Formulation and Device Patents<\/strong><\/h3>\n\n\n\n

New formulations \u2014 controlled-release, high-concentration, citrate-free, depot, subcutaneous \u2014 generate new patents that expire later than the COM patent. Devices (autoinjectors, on-body delivery systems) add another distinct patent layer. Humira’s high-concentration citrate-free formulation, approved in 2015, was patented separately from the original adalimumab molecule. AbbVie used those patents in the BPCIA dance against biosimilar manufacturers.<\/p>\n\n\n\n

The layer works because formulation switches change the practical product even if the molecule is identical. A biosimilar manufacturer that produces only the original concentration cannot substitute for a patient who has been transitioned to the new formulation.<\/p>\n\n\n\n

Common formulation strategies include:<\/p>\n\n\n\n

    \n
  • Concentration changes (low to high concentration injectables that reduce injection volume)<\/li>\n\n\n\n
  • Excipient switches (citrate to non-citrate formulations that reduce injection-site pain)<\/li>\n\n\n\n
  • Solid-state changes (amorphous versus crystalline polymorphs, hydrates, solvates)<\/li>\n\n\n\n
  • Particle engineering (micronization, nanoformulation, lipid nanoparticles)<\/li>\n<\/ul>\n\n\n\n

    Each of these can support multiple patents, and each typically requires a generic or biosimilar manufacturer to either replicate the formulation (incurring development cost and regulatory delay) or design around it (incurring formulation risk and potential bioequivalence issues).<\/p>\n\n\n\n

    Layer Two: Method of Use Patents<\/strong><\/h3>\n\n\n\n

    Method-of-use patents claim specific therapeutic applications of the molecule. They do not block a generic from being made, but they can block it from being marketed for the protected indication. The practical effect is to push generic manufacturers into ‘skinny labels’ that omit the patented indications. Skinny labeling has produced significant litigation \u2014 the GSK v. Teva carvedilol case, decided by the Federal Circuit in 2021, complicated the doctrine considerably by allowing ‘induced infringement’ theories even for label-deletion language.<\/p>\n\n\n\n

    For oncology drugs, method-of-use claims around specific tumor types, combination regimens, and biomarker-selected populations create real friction for biosimilar entry. Keytruda’s 38 approved indications and the dozens of combination regimens published since 2014 generate a substantial method-of-use estate. A biosimilar pembrolizumab launching with a skinny label that omits, say, the high-volume melanoma or non-small cell lung cancer indications would have a sharply reduced commercial opportunity.<\/p>\n\n\n\n

    The challenge for method-of-use defense is that the patents are inherently limited to specific uses. A physician prescribing the biosimilar for the protected indication may be ‘inducing infringement,’ but enforcement against thousands of prescribers is impractical. The realistic enforcement target is the biosimilar manufacturer’s label, marketing materials, and detailing practices.<\/p>\n\n\n\n

    Layer Three: Manufacturing Process Patents<\/strong><\/h3>\n\n\n\n

    Process patents claim specific methods of producing the molecule. For biologics, where the manufacturing process is functionally part of the product (cell line selection, purification, post-translational modification patterns), process patents are unusually powerful. A biosimilar manufacturer must develop its own process to avoid infringement, which is technically and financially demanding.<\/p>\n\n\n\n

    AbbVie’s Humira process patents covered cell culture media compositions, purification protocols, and quality control methods. Many were filed in the 2014\u20132018 window, well after the original COM patent. The patents claimed specific buffer systems, chromatography protocols, viral inactivation steps, and analytical methods. Each represented a potential infringement claim that a biosimilar manufacturer had to consider, even if any single patent might be designed around.<\/p>\n\n\n\n

    Biologic process patents are particularly difficult to challenge because the underlying manufacturing chemistry is complex and often proprietary. A biosimilar manufacturer cannot easily inspect the originator’s process; they have to develop their own and hope it does not read on the originator’s claims. The litigation discovery process can be revealing, but the burden of designing a non-infringing process falls on the biosimilar applicant.<\/p>\n\n\n\n

    Layer Four: Regulatory Exclusivities<\/strong><\/h3>\n\n\n\n

    Regulatory exclusivities are independent of patents and stack with them. The major U.S. exclusivities are:<\/p>\n\n\n\n

      \n
    • New Chemical Entity exclusivity: 5 years for novel small molecules<\/li>\n\n\n\n
    • BPCIA reference product exclusivity: 12 years for biologics<\/li>\n\n\n\n
    • Orphan Drug Exclusivity: 7 years for orphan-designated indications<\/li>\n\n\n\n
    • Pediatric exclusivity: 6 months added to existing patents and exclusivities<\/li>\n\n\n\n
    • New Chemical Indication exclusivity: 3 years for new indications of approved drugs<\/li>\n<\/ul>\n\n\n\n

      Pediatric exclusivity is mechanically the most valuable per dollar of trial cost. A pediatric study can extend every patent and exclusivity in the drug’s portfolio by six months simultaneously, which on a blockbuster translates into hundreds of millions to billions in additional revenue.<\/p>\n\n\n\n

      Layer Five: Successor Products<\/strong><\/h3>\n\n\n\n

      The most durable defense is a follow-on product that captures the same patient population with a new molecule, new patent runway, and ideally improved efficacy or convenience. Skyrizi and Rinvoq did this for AbbVie. Merck is attempting an analog with its TIGIT and LAG-3 programs and with the Prometheus tulisokibart acquisition for inflammatory bowel disease. Bristol-Myers Squibb is attempting it for Opdivo with combination immunotherapies and the Karuna acquisition for neurology.<\/p>\n\n\n\n

      This layer is the most expensive and slowest to develop. It also has the highest hit rate when it works. The companies that defended successfully in the 2011\u20132015 cliff \u2014 Novo Nordisk transitioning insulin franchises, Johnson & Johnson rebuilding around Stelara and Tremfya \u2014 used pipeline succession as the structural defense. The companies that did not succeed in the 2025\u20132030 cliff will be the ones whose pipelines did not deliver follow-ons in time.<\/p>\n\n\n\n

      The Patent Cliff Wave: 2025-2030<\/strong><\/h2>\n\n\n\n

      EvaluatePharma estimated in its 2023 World Preview that global branded pharmaceutical sales at risk from patent expiry between 2023 and 2028 total approximately $251 billion [31]. More recent forecasts, including from Global Pricing Innovations and DrugPatentWatch, put the figure at $300 billion to $400 billion through 2033 [30][32].<\/p>\n\n\n\n

      The 2025\u20132030 cliff differs from the 2011\u20132015 cliff in three ways:<\/p>\n\n\n\n

      Composition.<\/strong> The earlier cliff was dominated by oral small molecules in primary care (Lipitor, Plavix, Singulair, Diovan, Actos, Zyprexa, Seroquel). The current cliff is dominated by biologics and specialty drugs (Humira, Stelara, Eylea, Keytruda, Opdivo, Eliquis, Imbruvica) [33].<\/p>\n\n\n\n

      Erosion shape.<\/strong> Small-molecule cliffs produced near-vertical revenue drops (Lipitor: 80% in 24 months). Biologic cliffs produce slopes (Humira: 32% in year one, 38% in year two) [17][19]. The slope reflects biosimilar manufacturing complexity, interchangeability requirements, PBM rebate dynamics, and physician inertia.<\/p>\n\n\n\n

      Concentration risk.<\/strong> Several large pharma companies face proportionally larger exposure than in 2011\u20132015. BMS faces approximately 47% of revenue at risk by 2030 between Eliquis and Opdivo expirations [24]. Merck faces roughly 56% of revenue concentrated in Keytruda alone [24]. Pfizer faces $15+ billion in at-risk revenue from Prevnar, Ibrance, and Xtandi [24].<\/p>\n\n\n\n

      Eliquis: The Combined IRA and Patent Cliff Stress Case<\/strong><\/h3>\n\n\n\n

      The BMS\/Pfizer anticoagulant Eliquis (apixaban) faces a compounding stress test. Its composition of matter patent extends to 2026, with method-of-use patents potentially extending into 2031. The drug was also one of the first 10 drugs selected for Medicare drug price negotiation under the Inflation Reduction Act, with negotiated prices taking effect January 2026 [34].<\/p>\n\n\n\n

      The IRA negotiation effectively pulls forward part of the LOE financial impact. A drug that loses 40% of its Medicare price two years before its COM expires has a different revenue trajectory than one that does not. BMS’s revenue projections through 2030 reflect both stressors stacking.<\/p>\n\n\n\n

      Stelara: Biosimilar Entry in 2025<\/strong><\/h3>\n\n\n\n

      Johnson & Johnson’s Stelara (ustekinumab) lost composition of matter protection in late 2023, but settlements with biosimilar manufacturers \u2014 Amgen’s Wezlana, Alvotech and Teva’s Selarsdi, Celltrion’s Steqeyma, others \u2014 pushed U.S. biosimilar entry to 2025. The Stelara case is being read by the industry as a near-real-time analog for Keytruda: a biologic with patent thicket protection that delayed entry several years past the core patent expiration.<\/p>\n\n\n\n

      Why Biosimilar Erosion Looks Different From Generic Erosion<\/strong><\/h2>\n\n\n\n

      Three structural differences between small-molecule generics and biosimilars produce the different erosion shapes.<\/p>\n\n\n\n

      Manufacturing Complexity<\/strong><\/h3>\n\n\n\n

      A small-molecule generic costs $1\u20134 million and takes 1\u20132 years to develop. A biosimilar costs $100\u2013300 million and takes 5\u20138 years [35]. The economics dictate that only a few biosimilar manufacturers exist for any given reference product, which limits price competition. Humira had 10 biosimilars within 18 months of launch, but that is unusually high; most biologics see two to four biosimilars in the first three years.<\/p>\n\n\n\n

      Interchangeability<\/strong><\/h3>\n\n\n\n

      Under U.S. law, a generic small molecule with an AB rating from the FDA can be substituted at the pharmacy without prescriber involvement. A biosimilar requires the prescriber to write for the biosimilar specifically \u2014 unless the FDA has designated it as ‘interchangeable,’ which requires additional comparative use studies. As of 2024, only a handful of biosimilars have interchangeability designations. Boehringer Ingelheim’s Cyltezo was the first interchangeable Humira biosimilar; others have followed [36].<\/p>\n\n\n\n

      Without interchangeability, biosimilar adoption depends primarily on payer formulary decisions and physician prescribing patterns, both of which move slowly.<\/p>\n\n\n\n

      PBM Rebate Dynamics<\/strong><\/h3>\n\n\n\n

      Pharmacy benefit managers earn rebates based on list prices, which gives them an interest in maintaining high-list-price brands on formularies even when biosimilars exist at lower list prices. AbbVie reportedly offered aggressive rebates to PBMs in 2023 to keep Humira on commercial formularies, which is why Humira’s net price per prescription actually fell below biosimilar net prices in Q4 2023 ($2,798 for Humira versus $3,452\u2013$4,793 for biosimilars) despite biosimilars having lower list prices [37].<\/p>\n\n\n\n

      The CVS Caremark April 2024 decision to remove Humira from major formularies in favor of Sandoz’s Hyrimoz (via CVS’s Cordavis subsidiary) was the structural event that finally accelerated Humira’s decline. The lesson: payer behavior, not patent expiration, determines the actual timing of biosimilar erosion.<\/p>\n\n\n\n

      The Economics of Effective Patent Life<\/strong><\/h2>\n\n\n\n

      The 20-year patent term is misleading as a planning input. A pharmaceutical company files its COM patent early in discovery, often 2\u20134 years before IND-enabling studies. The molecule then spends 8\u201312 years in clinical development and FDA review. By the time the drug launches, 10\u201314 years of the patent term have already elapsed [5].<\/p>\n\n\n\n

      Patent Term Extensions partially compensate for regulatory delay. Under 35 U.S.C. \u00a7156, a sponsor can apply for an extension of up to five years on one patent per drug, with a hard cap of 14 years total effective market exclusivity from FDA approval. Keytruda received a PTE that pushed certain claims into 2029. Humira’s PTE pushed adalimumab’s core claim from 2014 to 2016.<\/p>\n\n\n\n

      For analysts modeling pharma equity, the gap between nominal patent expiration and effective LOE is where most of the valuation work happens. DrugPatentWatch’s analysis frames this as a probabilistic cash flow duration: ‘A drug with a single composition-of-matter patent expiring in three years trades differently than one with overlapping formulation, method-of-use, and device patents extending effective exclusivity by six-plus years. The delta between those two scenarios frequently explains valuation gaps that screen as cheap on conventional multiples’ [38].<\/p>\n\n\n\n

      Patent Term Adjustment Versus Patent Term Extension<\/strong><\/h3>\n\n\n\n

      These are easy to conflate. Patent Term Adjustment (PTA) is granted under 35 U.S.C. \u00a7154(b) for USPTO delays during prosecution. PTA is automatic, applied at issuance, and can add days, months, or in extreme cases years. Patent Term Extension (PTE) is granted under \u00a7156 to compensate for FDA regulatory delay. PTE requires an application within 60 days of FDA approval, is limited to one patent per product, and caps at five years.<\/p>\n\n\n\n

      Both stack with the underlying 20-year term, but they apply to different patents in a portfolio. A well-managed estate uses PTA on the early COM patent and PTE on a later formulation or method patent to maximize total protected runway.<\/p>\n\n\n\n

      The Inflation Reduction Act Changes the Calculus<\/strong><\/h2>\n\n\n\n

      The IRA’s Medicare drug price negotiation provisions, enacted in 2022, allow CMS to negotiate prices for selected high-spend drugs starting 9 years after launch for small molecules and 13 years after launch for biologics [34]. The first ten drugs selected, with negotiated prices effective January 2026, included Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp.<\/p>\n\n\n\n

      The structural effect on lifecycle management is twofold:<\/p>\n\n\n\n

      It shortens the economic patent life.<\/strong> A drug whose price is forced down at year 9 (small molecule) or 13 (biologic) effectively loses part of its monopoly years before its patents expire. The traditional lifecycle management calculus \u2014 file secondary patents to extend exclusivity past the COM cliff \u2014 has to account for the IRA price drop occurring before the COM expires.<\/p>\n\n\n\n

      It changes the formulation switching logic.<\/strong> Under the original IRA framework, an IV-to-SC switch like Keytruda Qlex could potentially reset the clock if the SC product is treated as a separate drug for negotiation purposes. The legal question is unsettled, and CMS has signaled that it intends to scrutinize ‘product hopping’ that appears designed to evade negotiation. Whether Keytruda Qlex restarts Keytruda’s 13-year negotiation clock will be litigated.<\/p>\n\n\n\n

      What Lipitor Could Not Do That Humira Could<\/strong><\/h2>\n\n\n\n

      Pfizer tried multiple Lipitor lifecycle defenses. None worked materially.<\/p>\n\n\n\n

      The Pfizer playbook included an over-the-counter Lipitor application (rejected by FDA), a coupon program that subsidized branded refills below the generic copay tier (effective at slowing erosion for roughly 6 months), and a co-marketing arrangement with Watson Pharmaceuticals to launch an authorized generic during the 180-day exclusivity period [39]. These tactics shifted timing by months but did not change the trajectory.<\/p>\n\n\n\n

      The structural reason: Lipitor was a simple oral small molecule with no formulation barriers, low brand loyalty, and high payer motivation for substitution. The Hatch-Waxman pathway delivered multiple generic entrants within months. There was no biologic complexity for AbbVie-style thicket defense to exploit.<\/p>\n\n\n\n

      The lesson \u2014 and it generalizes \u2014 is that the menu of defensive options is set by the molecule’s structural attributes, not by management ingenuity. AbbVie’s lawyers were not smarter than Pfizer’s lawyers. AbbVie had a biologic with BPCIA mechanics. Pfizer had a small molecule with Hatch-Waxman mechanics. The available defenses differed by an order of magnitude.<\/p>\n\n\n\n

      The Advair Counterexample<\/strong><\/h3>\n\n\n\n

      GSK’s asthma combination Advair (fluticasone\/salmeterol) provides a useful intermediate case. The drug is technically a small-molecule combination, but it is delivered through a patented Diskus device. The device complexity created a qualitative barrier that delayed generic entry by years past the COM expiration. The first AB-rated generic (Mylan’s Wixela) launched in 2019, more than two years past the COM expiration, and Advair retained meaningful share for years after that [40].<\/p>\n\n\n\n

      The Advair case demonstrates that even small molecules can produce slope-shaped erosion when delivery complexity creates a barrier. Inhaled drugs, transdermal patches, sterile injectables, and complex sustained-release formulations all extend the regulatory and manufacturing burden on would-be generic entrants by 12\u201324 months.<\/p>\n\n\n\n

      What Resilient Companies Actually Do Before the Cliff<\/strong><\/h2>\n\n\n\n

      Across the case studies \u2014 Humira, Lipitor, Plavix, Singulair, Advair, Stelara \u2014 a consistent pattern of pre-cliff actions distinguishes companies that retain pricing power from those that do not.<\/p>\n\n\n\n

      Start the Pipeline Pivot Eight Years Out<\/strong><\/h3>\n\n\n\n

      AbbVie began Phase 3 trials for Rinvoq in 2016, eight years before Humira’s biosimilar entry. Skyrizi entered Phase 3 around 2015. Merck’s pivot away from pure pembrolizumab dependence \u2014 including the Acceleron acquisition for sotatercept in 2021 and the Prometheus acquisition for tulisokibart in 2023 \u2014 began roughly seven years before Keytruda’s expected 2028 expiration [41].<\/p>\n\n\n\n

      The eight-year window matters because a Phase 3 program plus regulatory review plus commercial scaling takes roughly that long. A company that starts the pivot four years before the cliff will not have a multi-billion-dollar follow-on franchise ready when the cliff hits.<\/p>\n\n\n\n

      File Secondary Patents Continuously<\/strong><\/h3>\n\n\n\n

      AbbVie’s secondary patent filings on Humira accelerated after 2014, but the foundation was laid in the early 2000s. Process patents, formulation patents, and method-of-use patents were filed throughout the product’s commercial life. The total count of 247 applications reflects roughly 17 years of continuous filing activity.<\/p>\n\n\n\n

      Companies that wait until the cliff is visible to start filing secondary patents discover that USPTO examination takes 2\u20134 years and that obviousness rejections become harder to overcome the closer the filing date is to the original COM patent. The patent thicket is a long-horizon project.<\/p>\n\n\n\n

      Build Payer Relationships, Not Just Patents<\/strong><\/h3>\n\n\n\n

      The Humira case demonstrated that PBM rebate structures determined the timing of biosimilar uptake more than patent litigation did. AbbVie’s rebate strategy kept Humira on commercial formularies through 2023 and most of 2024 even as biosimilars were available at 85% lower list prices [37].<\/p>\n\n\n\n

      The implication for companies approaching cliffs: commercial contracting infrastructure matters as much as IP. A drug with a strong PBM rebate posture can outlast its patent expiration commercially. A drug without one \u2014 particularly in therapeutic classes where biosimilar interchangeability is strong \u2014 cannot.<\/p>\n\n\n\n

      Use Pediatric Exclusivity Tactically<\/strong><\/h3>\n\n\n\n

      Pediatric exclusivity provides 6 months of additional protection across all of a drug’s patents and exclusivities simultaneously. The trials required are typically modest in cost compared to the revenue protected. AbbVie obtained pediatric exclusivity on Humira. Pfizer did not on Lipitor. Six months on a $20 billion product is $10 billion of revenue retention. The ROI on a $20\u201350 million pediatric study is asymmetric.<\/p>\n\n\n\n

      Plan the Reformulation Three Years Before Approval<\/strong><\/h3>\n\n\n\n

      The Keytruda Qlex reformulation was approved in September 2025, three years before the 2028 cliff. That timing reflects the minimum commercial runway needed to transition meaningful patient share before biosimilars arrive. Davis projects 30\u201340% conversion by 2027, with continued ramp post-cliff [25].<\/p>\n\n\n\n

      A reformulation approved 12 months before the cliff cannot convert enough patients. A reformulation approved 5 years before the cliff cannibalizes premium-priced franchise revenue unnecessarily. The 3-year window is roughly the optimum.<\/p>\n\n\n\n

      Where DrugPatentWatch Fits Into the Analysis<\/strong><\/h2>\n\n\n\n

      The kind of analysis this article performs depends on access to structured patent data \u2014 Orange Book and Purple Book listings, patent term adjustments, FDA exclusivities, generic and biosimilar approvals, and litigation status. DrugPatentWatch aggregates this data across U.S. and major international markets, including patent expiry dates, Paragraph IV certifications, and exclusivity stacking calculations.<\/p>\n\n\n\n

      For an investor modeling a pharma equity’s terminal value, the structured data matters more than the narrative. A drug whose COM patent expires in 2027 but whose formulation patents extend to 2031 with pediatric exclusivity carries a different cash flow profile than one with no secondary protection. For a generic or biosimilar manufacturer planning a Paragraph IV or 351(k) filing, the patent landscape determines the litigation budget and the probability-weighted launch date. The data is the analysis.<\/p>\n\n\n\n

      Two Forecasts That Drive the 2026\u20132030 Outlook<\/strong><\/h2>\n\n\n\n

      Looking forward through 2030, two specific forecasts seem to me most relevant for sector-level positioning.<\/p>\n\n\n\n

      Forecast One: Biosimilar Penetration Will Vary More by Therapeutic Class Than by Patent Strength<\/strong><\/h3>\n\n\n\n

      Humira’s biosimilar penetration depended primarily on PBM formulary decisions, not patent expiration. Once CVS Caremark moved in April 2024, share shifted in months. Once Express Scripts and OptumRx followed in 2024\u20132025, the trajectory accelerated. The patent thicket bought time, but the payer system determined the post-cliff trajectory.<\/p>\n\n\n\n

      For Keytruda, the relevant payer dynamic is different. Oncology drugs flow through medical benefit channels with different rebate structures, different prescriber dynamics (cancer centers and large oncology practices), and different patient-out-of-pocket structures (typically lower because of catastrophic coverage). The 2028 Keytruda biosimilar trajectory will likely look more like the Stelara trajectory than the Humira trajectory \u2014 slower, more concentrated in academic medical centers initially, then expanding as community oncology converts.<\/p>\n\n\n\n

      Forecast Two: IRA Negotiation Will Compress the Effective Patent Life Across the Sector<\/strong><\/h3>\n\n\n\n

      The first ten IRA-negotiated drugs see prices effective January 2026. The next batches expand annually. By 2030, the cumulative effect is that essentially all blockbuster small molecules see meaningful Medicare price reductions 9 years after launch, and all biologic blockbusters see them at 13 years.<\/p>\n\n\n\n

      For lifecycle planning, this means the economic value of patent extensions past those points is lower. A formulation patent that extends a small molecule’s protection from year 12 to year 15 is worth less under IRA pricing than it was before. The strategic response many companies are taking is to push for shorter clinical development times and faster launches, which extends the pre-IRA monopoly window. The implication for pipeline strategy is that platforms enabling faster Phase 3 (real-world evidence integration, biomarker-selected enrollment, decentralized trial designs) gain commercial premium.<\/p>\n\n\n\n

      Key Takeaways<\/strong><\/h2>\n\n\n\n
        \n
      • Composition of matter patents are the only patents a generic or biosimilar cannot work around. Every other patent in the estate is contestable. The COM cliff defines the latest possible date for serious revenue defense to be in place.<\/li>\n\n\n\n
      • AbbVie extended Humira’s effective monopoly seven years past its 2016 COM expiration through a 247-application patent thicket and biosimilar settlements. The defense worked because the BPCIA places no cap on patents asserted against biosimilars.<\/li>\n\n\n\n
      • Pfizer’s Lipitor lost 80% of U.S. revenue within 24 months of its 2011 cliff despite all available defenses. Small molecules under Hatch-Waxman have no equivalent thicket option.<\/li>\n\n\n\n
      • Merck’s Keytruda Qlex subcutaneous launch in September 2025 is the largest real-time lifecycle reformulation ever attempted, with the explicit goal of converting 30\u201340% of patients to the SC formulation before 2028.<\/li>\n\n\n\n
      • The 2025\u20132030 patent cliff exposes $300\u2013400 billion in branded revenue, dominated by biologics rather than small molecules, which produces slope-shaped rather than cliff-shaped erosion.<\/li>\n\n\n\n
      • Effective lifecycle defense requires action 8 years before the cliff: pipeline succession, continuous secondary patent filing, payer relationship infrastructure, pediatric exclusivity, and reformulation timed to a 3-year pre-cliff approval window.<\/li>\n\n\n\n
      • The IRA’s Medicare price negotiation compresses effective patent life across the sector, reducing the marginal value of late-stage formulation patents and increasing the premium on faster clinical development.<\/li>\n<\/ul>\n\n\n\n

        FAQ<\/strong><\/h2>\n\n\n\n

        How long after a composition of matter patent expires do generics or biosimilars typically launch?<\/strong><\/h3>\n\n\n\n

        For small molecules under Hatch-Waxman, generics typically launch within 0\u20136 months of COM expiration, often the same day if a Paragraph IV challenger has secured 180-day exclusivity. For biologics under the BPCIA, the gap between COM expiration and first biosimilar launch averages 2\u20137 years, depending on the depth of the secondary patent estate. Humira’s was 7 years. Stelara’s was approximately 2 years.<\/p>\n\n\n\n

        Can a subcutaneous reformulation actually delay biosimilar competition?<\/strong><\/h3>\n\n\n\n

        It cannot legally delay biosimilar approval or launch \u2014 the IV biosimilar can enter the market on schedule. What it can do is shift the patient population off the IV formulation before biosimilars arrive, reducing the addressable market for the biosimilar. Whether this ‘product hop’ succeeds depends on how rapidly patients transition, whether payers cover the reformulated version preferentially, and whether antitrust or product-hopping legislation closes the strategy. Merck is currently testing this with Keytruda Qlex.<\/p>\n\n\n\n

        Why does AbbVie’s Skyrizi succeed where many follow-on drugs fail?<\/strong><\/h3>\n\n\n\n

        Skyrizi (risankizumab-rzaa) is mechanistically distinct from Humira \u2014 it targets IL-23 rather than TNF-\u03b1 \u2014 and demonstrated superior efficacy in psoriasis trials. The follow-on drugs that fail typically have me-too mechanisms with marginal clinical differentiation. The premium that payers and patients pay for a switched product depends on whether the new molecule provides meaningful clinical benefit. AbbVie spent roughly $14 billion acquiring Skyrizi from Boehringer Ingelheim in 2019 partly because the clinical data supported a real differentiation premise.<\/p>\n\n\n\n

        How should an institutional investor model patent cliff risk?<\/strong><\/h3>\n\n\n\n

        The conventional approach \u2014 discount the cliff year and reduce revenue 80% in year one \u2014 overstates the cliff for biologics and understates the pre-cliff IRA negotiation impact. A better approach models effective LOE as a probabilistic cash flow duration: weight the COM expiration date by the probability of secondary patent survival, adjust for therapeutic class biosimilar dynamics, and overlay IRA price reductions at the relevant 9-year or 13-year mark. Tools like DrugPatentWatch’s patent expiry database provide the structured inputs for this kind of modeling.<\/p>\n\n\n\n

        Is the patent thicket strategy still viable post-Humira?<\/strong><\/h3>\n\n\n\n

        It remains viable under current law, though the political and regulatory pressure has increased. The Senate Judiciary Committee approved bipartisan bills targeting product hopping and patent thicketing in 2025, and the USPTO has issued guidance encouraging examiners to scrutinize obviousness-type double patenting more aggressively. None of these changes prevent a thicket strategy, but they raise the cost. The Keytruda thicket litigation, expected to begin in 2026, will be the next data point on whether thicket defenses still hold at scale.<\/p>\n\n\n\n

        References<\/strong><\/h2>\n\n\n\n
          \n
        1. DrugPatentWatch. (2026, March 22). What happens when a drug patent expires? Understanding drug patent life.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/what-happens-when-a-drug-patent-expires\/<\/li>\n\n\n\n
        2. Arnold & Porter. (2020, June). Federal court rejects antitrust challenge to AbbVie’s Humira ‘patent thicket’.<\/em> https:\/\/www.arnoldporter.com\/en\/perspectives\/advisories\/2020\/06\/federal-court-rejects-antitrust-challenge<\/li>\n\n\n\n
        3. Bloomberg Law. (2025, May 8). Merck’s new Keytruda shot is a rare real-time ‘product hop’.<\/em> https:\/\/news.bloomberglaw.com\/ip-law\/mercks-new-keytruda-shot-is-a-rare-real-time-product-hop<\/li>\n\n\n\n
        4. DrugPatentWatch. (2026, March 22). When do drug patents expire: Understanding the lifecycle of pharmaceutical innovations.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/when-do-drug-patents-expire\/<\/li>\n\n\n\n
        5. DrugPatentWatch. (2026, March 23). How long does a drug patent actually last? The definitive analyst’s guide.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/how-long-does-a-patent-last-for-drugs\/<\/li>\n\n\n\n
        6. Alcimed. (2025, October 27). Patent cliff: What strategies can help biopharma stay competitive?<\/em> https:\/\/www.alcimed.com\/en\/insights\/patent-cliff\/<\/li>\n\n\n\n
        7. DrugPatentWatch. (2026, March 12). The patent cliff’s shadow: Impact on branded competitor drug sales.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/the-effect-of-patent-expiration-on-sales-of-branded-competitor-drugs-in-a-therapeutic-class\/<\/li>\n\n\n\n
        8. DrugPatentWatch. (2026, February 11). The ‘patent cliff’ revisited: Predicting stock impacts of patent expiry.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/the-patent-cliff-revisited-predicting-stock-impacts-of-patent-expiry\/<\/li>\n\n\n\n
        9. DrugPatentWatch. (2025, November 4). The thicket maze: A strategic guide to navigating and dismantling drug patent fortresses.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/the-thicket-maze-a-strategic-guide-to-navigating-and-dismantling-drug-patent-fortresses\/<\/li>\n\n\n\n
        10. BioSpace. (2024, July 12). AbbVie’s Humira continues to lose market share as biosimilars gain ground.<\/em> https:\/\/www.biospace.com\/business\/abbvies-humira-continues-to-lose-market-share-as-biosimilars-gain-ground-report<\/li>\n\n\n\n
        11. BioPharma Dive. (2023, January 27). Two decades and $200 billion: AbbVie’s Humira monopoly nears its end.<\/em> https:\/\/www.biopharmadive.com\/news\/humira-abbvie-biosimilar-competition-monopoly\/620516\/<\/li>\n\n\n\n
        12. Hustad, R. (2022). Competing with patent thickets. Boston University Law Review.<\/em> https:\/\/www.bu.edu\/bulawreview\/files\/2022\/03\/HUSTAD.pdf<\/li>\n\n\n\n
        13. Petrie-Flom Center, Harvard Law School. (2021, January 6). AbbVie wins first round in Humira antitrust lawsuit.<\/em> https:\/\/petrieflom.law.harvard.edu\/2021\/01\/06\/abbvie-humira-antitrust-patent-thicket\/<\/li>\n\n\n\n
        14. Biosimilars Law Bulletin. (2021, April 15). 7th Circuit hears oral arguments in Humira ‘patent thicket’ antitrust case.<\/em> https:\/\/www.biosimilarsip.com\/2021\/04\/15\/7th-circuit-hears-oral-arguments-in-humira-patent-thicket-antitrust-case\/<\/li>\n\n\n\n
        15. Mintz. (2020, June 18). AbbVie’s enforcement of its ‘patent thicket’ for Humira under antitrust scrutiny.<\/em> https:\/\/www.mintz.com\/insights-center\/viewpoints\/2231\/2020-06-18-abbvies-enforcement-its-patent-thicket-humira-under<\/li>\n\n\n\n
        16. Managed Healthcare Executive. (2024). AbbVie plays its ace cards against Humira’s decline.<\/em> https:\/\/www.managedhealthcareexecutive.com\/view\/abbvie-plays-its-ace-cards-against-humira-s-decline<\/li>\n\n\n\n
        17. AbbVie Inc. (2024). Form 8-K full year and fourth quarter 2023 results. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001551152\/000155115224000007\/abbv-20231231xexhibit991.htm<\/li>\n\n\n\n
        18. Fierce Pharma. (2024, July 12). AbbVie’s Humira loses some ground in high-stakes battle against biosimilars.<\/em> https:\/\/www.fiercepharma.com\/pharma\/shrinking-market-share-abbvies-humira-loses-ground-battle-against-biosimilars-report<\/li>\n\n\n\n
        19. BioSpace. (2025, March 26). Humira biosimilars gain ground as doctors adjust and new therapies rise.<\/em> https:\/\/www.biospace.com\/business\/humira-biosimilars-gain-ground-as-doctors-adjust-and-new-therapies-rise<\/li>\n\n\n\n
        20. AbbVie Inc. (2024, February 2). Reports full-year and fourth-quarter 2023 financial results. https:\/\/investors.abbvie.com\/news-releases\/news-release-details\/abbvie-reports-full-year-and-fourth-quarter-2023-financial<\/li>\n\n\n\n
        21. AbbVie Inc. (2024). Form 8-K first quarter 2024 results. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001551152\/000155115224000016\/abbv-20240331xexhibit991.htm<\/li>\n\n\n\n
        22. Yahoo Finance. (2025, January 14). Merck races to launch subcutaneous Keytruda amid looming patent expiry for IV version.<\/em> https:\/\/finance.yahoo.com\/news\/merck-races-launch-subcutaneous-keytruda-134303269.html<\/li>\n\n\n\n
        23. BioSpace. (2025, September 22). As exclusivity loss looms, Merck wins subcutaneous approval for Keytruda.<\/em> https:\/\/www.biospace.com\/fda\/as-exclusivity-loss-looms-merck-wins-subcutaneous-approval-for-keytruda<\/li>\n\n\n\n
        24. DeepCeutix. (2026, February 2). $300 billion in pharma revenue loses patent protection by 2030.<\/em> https:\/\/deepceutix.com\/insights\/patent-cliff-reformulation<\/li>\n\n\n\n
        25. ProactRx. (2025, November 14). FDA approved Keytruda Qlex to offset original drug’s patent expiration in 2028.<\/em> https:\/\/secure.proactrx.com\/resource\/news\/fda-approved-keytruda-qlex-to-offset-original-drugs-patent-expiration-in-2028\/500\/<\/li>\n\n\n\n
        26. Bloomberg Law. (2025, May 8). Merck’s new Keytruda shot is a rare real-time ‘product hop’.<\/em> https:\/\/news.bloomberglaw.com\/ip-law\/mercks-new-keytruda-shot-is-a-rare-real-time-product-hop<\/li>\n\n\n\n
        27. I-MAK. (2025, May 5). Merck’s scheme to product hop Keytruda.<\/em> https:\/\/www.i-mak.org\/2025\/05\/05\/mercks-scheme-to-product-hop-keytruda\/<\/li>\n\n\n\n
        28. BioSpace. (2025, September 22). As exclusivity loss looms, Merck wins subcutaneous approval for Keytruda.<\/em> https:\/\/www.biospace.com\/fda\/as-exclusivity-loss-looms-merck-wins-subcutaneous-approval-for-keytruda<\/li>\n\n\n\n
        29. BioPharma Dive. (2024, February 1). Merck keeps deal focus with Keytruda patent cliff on horizon.<\/em> https:\/\/www.biopharmadive.com\/news\/merck-dealmaking-15-billion-keytruda-cliff-davis\/706309\/<\/li>\n\n\n\n
        30. DrugPatentWatch. (2026, February 25). Beyond the drug patent cliff: How procurement can drive immediate savings with generics and biosimilars.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/beyond-the-drug-patent-cliff-how-procurement-can-drive-immediate-savings-with-generics-and-biosimilars\/<\/li>\n\n\n\n
        31. DrugPatentWatch. (2026, March 4). Predict the patent cliff: The patent cliff is coming.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/predict-the-patent-cliff\/<\/li>\n\n\n\n
        32. DrugPatentWatch. (2026, February 7). Kill the patent cliff: How to turn a $400 billion revenue loss into a competitive edge.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/kill-the-patent-cliff-how-to-turn-a-400-billion-revenue-loss-into-a-competitive-edge\/<\/li>\n\n\n\n
        33. DrugPatentWatch. (2026, March 12). The $236 billion cliff: How pharma loses its blockbusters and what replaces them.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/as-blockbuster-drugs-fizzle-biotech-looks-warily-to-the-next-big-thing\/<\/li>\n\n\n\n
        34. Global Pricing Innovations. (2025, November 4). Patent cliff in pharma: Navigating disruption and creating opportunity.<\/em> https:\/\/globalpricing.com\/patent-cliff-in-pharma-navigating-disruption-and-creating-opportunity\/<\/li>\n\n\n\n
        35. DrugPatentWatch. (2026, January 9). Beyond the patent cliff: 15 strategies for pharmaceutical lifecycle management.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/beyond-the-patent-cliff-15-strategies-for-pharmaceutical-lifecycle-management\/<\/li>\n\n\n\n
        36. Rome, B. N., et al. (2024). Use, spending, and prices of adalimumab following biosimilar competition. JAMA Health Forum.<\/em> https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11645644\/<\/li>\n\n\n\n
        37. Rome, B. N., et al. (2024). Use, spending, and prices of adalimumab following biosimilar competition. JAMA Health Forum.<\/em> https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11645644\/<\/li>\n\n\n\n
        38. DrugPatentWatch. (2026, March 22). Drug patent strategy: The definitive guide for pharmaceutical IP teams, R&D leads, and institutional investors.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/optimizing-your-drug-patent-strategy-a-comprehensive-guide-for-pharmaceutical-companies\/<\/li>\n\n\n\n
        39. DrugPatentWatch. (2026, February 20). The patent cliff panic: A pain point every pharma investor faces.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/the-patent-cliff-panic-a-pain-point-every-pharma-investor-faces\/<\/li>\n\n\n\n
        40. DrugPatentWatch. (2025, December 9). A framework for multi-year pharmaceutical patent cliff impact modeling and strategic response.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/a-framework-for-multi-year-pharmaceutical-patent-cliff-impact-modeling-and-strategic-response\/<\/li>\n\n\n\n
        41. BioPharma Dive. (2023, February 21). Big pharma’s looming threat: A patent cliff of ‘tectonic magnitude’.<\/em> https:\/\/www.biopharmadive.com\/news\/pharma-patent-cliff-biologic-drugs-humira-keytruda\/642660\/<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

          A composition of matter patent is the only piece of pharmaceutical intellectual property that a generic or biosimilar manufacturer cannot […]<\/p>\n","protected":false},"author":1,"featured_media":38849,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38845","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38845"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38845\/revisions"}],"predecessor-version":[{"id":39273,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38845\/revisions\/39273"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38849"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}